Trial Profile

A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Bleximenib (Primary) ; Cytarabine (Primary) ; Doxorubicin (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

12 Jun 2025 According to a Johnson & Johnson media release, Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib were featured in an oral presentation at the 2025 European Hematology Association (EHA) Congress (S137).
12 Jun 2025 Results presented in the Johnson & Johnson Media Release.
28 Mar 2025 Planned primary completion date changed from 5 Mar 2025 to 5 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com